review
provid
integr
scenario
relev
aspect
develop
use
drug
provid
natur
sourc
recent
advanc
biosynthesi
structur
design
antimicrobi
peptid
antiinfect
drug
key
role
contemporari
world
contribut
dramat
decreas
mortal
rate
caus
infecti
diseas
worldwid
antimicrobi
peptid
amp
multifunct
effector
innat
immun
system
mucos
surfac
present
antimicrobi
activ
rang
pathogen
virus
bacteria
fungi
howev
discoveri
develop
new
antibacteri
drug
crucial
step
overcom
great
challeng
pose
emerg
antibiot
resist
review
outlin
recent
advanc
develop
novel
amp
improv
antimicrobi
activ
achiev
characterist
structur
design
addit
describ
recent
progress
made
overcom
major
limit
hinder
peptid
biosynthesi
drug
current
use
therapeut
obtain
natur
occur
molecul
purifi
microorgan
plant
anim
estim
antiinfect
agent
base
natur
product
scaffold
account
approv
antibacteri
new
chemic
entiti
nce
thu
attest
import
natur
product
main
sourc
therapeut
pathogen
bacteria
context
microorgan
notabl
member
gramposit
phylum
actinomycet
workhous
sourc
clinic
approv
antibacteri
agent
high
divers
candid
molecul
extract
microorgan
frequent
lead
discoveri
new
compound
distinct
mechan
action
compar
drug
current
use
clinic
purpos
howev
recent
year
tradit
screen
drug
candid
belong
complet
new
antibacteri
class
microbi
sourc
suffer
consider
declin
mostli
presenc
numer
alreadi
wellcharacter
molecul
scenario
particularli
worrisom
increas
emerg
bacteri
resist
antibiot
notabl
develop
countri
widespread
indiscrimin
use
antibiot
clinic
veterinari
purpos
search
new
therapeut
molecul
commerci
applic
ongo
pharmaceut
industri
focus
drug
prospect
also
modif
exist
antibiot
time
fashion
meet
custom
need
among
divers
natur
occur
antiinfect
agent
discov
date
amp
particularli
import
molecul
versatil
highli
specif
antimicrobi
compound
constitut
promis
candid
commerci
clinic
use
amp
essenti
compon
innat
immun
system
vertebr
nonspecif
host
defens
system
plant
fungi
invertebr
evolv
billion
year
ago
potent
antiinfect
agent
differ
virus
bacteria
fungi
parasit
small
peptid
usual
compris
amino
acid
residu
kda
size
commonli
show
cation
structur
rich
posit
charg
arginin
lysin
residu
favor
interact
peptid
microbi
cytoplasm
membran
howev
although
less
common
also
anion
amp
notabl
plant
amp
usual
kill
pathogen
interact
membran
phospholipid
result
membran
permeabil
subsequ
disrupt
peptid
also
show
differ
secondari
structur
bsheet
stabil
two
three
disulfid
bridg
often
display
helic
amphipath
structur
amp
target
varieti
essenti
metabol
process
plasma
membran
extraand
intracellular
site
frequent
exhibit
immunomodulatori
properti
stimul
cytokin
product
repress
inflamm
kill
cancer
cell
promot
wound
heal
eukaryot
natur
amp
encod
specif
gene
constitut
express
basal
level
rapidli
transcrib
induct
contact
exposit
invad
pathogen
therebi
varieti
differ
amp
found
simultan
organ
plant
respons
pathogen
stimuli
differ
organ
root
seed
flower
stem
leav
recent
advanc
silico
drug
design
highthroughput
screen
compound
librari
base
proteinprotein
interact
trigger
grow
interest
discoveri
new
antibacteri
drug
microbi
plant
anim
origin
effort
contribut
uncov
varieti
molecul
novel
structur
improv
current
avail
class
antibiot
blactam
ketolid
macrolid
glycopeptid
aminoglycosid
oxazolidinon
antiinfect
agent
use
viral
vector
base
tobacco
mosaic
viru
tmv
potato
viru
x
pvx
clone
massiv
express
amp
gene
nicotiana
benthamiana
appear
interest
new
approach
consider
enhanc
recombin
peptid
product
structur
function
character
rapid
highthroughput
stagger
biosynthesi
peptid
use
agroinfiltr
leav
n
benthamiana
constitut
promis
strategi
deliv
new
antigen
peptid
vaccin
candid
address
interest
mani
privat
state
health
institut
final
gene
edit
use
cluster
regularli
interspac
short
palindrom
repeat
crispr
crisprassoci
protein
ca
system
anoth
molecular
tool
could
revolution
recombin
biosynthesi
amp
approach
specif
target
dna
sequenc
ad
remov
replac
dna
segment
mediat
cellular
dna
repair
mechan
sitespecif
doublestrand
break
allow
edit
specif
gene
within
host
genom
integr
fragment
contain
code
sequenc
particular
amp
hotspot
site
enabl
increas
amp
biosynthesi
work
casetocas
scenario
express
strategi
could
overcom
major
drawback
product
amp
notabl
low
biosynthesi
level
present
plant
anim
amp
antimicrobi
activ
given
amp
specif
relat
amino
acid
composit
physic
chemic
properti
posit
net
charg
flexibl
size
hydrophob
amphipath
margin
chang
peptid
residu
sequenc
normal
follow
major
chang
antimicrobi
activ
amp
present
differ
mechan
action
mani
well
describ
literatur
molecular
interact
amp
microorgan
reli
varieti
target
present
microorgan
particularli
gramposit
gramneg
bacteria
gener
mechan
action
amp
classifi
two
basic
group
disrupt
mechan
associ
membran
lysi
ii
membran
undisrupt
mechan
focu
neutral
intracellular
target
independ
propos
group
first
step
mechan
molecular
interact
amp
cytoplasm
membran
drive
forc
interact
electrostat
forc
present
amp
normal
cation
polyanion
surfac
bacteria
differ
cell
wall
composit
among
bacteri
group
affect
directli
mode
action
amp
gramneg
bacteria
present
three
major
layer
cell
envelop
outer
membran
om
compris
lipid
bilay
mostli
lipopolysaccharid
lp
interlac
teichoic
acid
major
role
protect
environ
ii
peptidoglycan
cell
wall
compris
repeat
unit
disaccharid
nacetyl
glucosaminenacetylmuram
acid
link
pentapeptid
side
chain
iii
cytoplasm
membranephospholipid
bilay
contrast
gramposit
bacteria
om
peptidoglycan
layer
thicker
gramneg
bacteria
disrupt
mechan
present
four
classic
model
toroid
model
ii
carpet
model
iii
aggreg
model
iv
barrel
model
recent
new
disrupt
model
model
indirectli
associ
membran
disrupt
describ
disord
toroid
model
ii
membran
thinningthicken
model
iii
charg
lipid
cluster
model
iv
nonbilay
intermedi
model
v
oxid
lipid
target
model
vi
anion
carrier
model
vii
nonlyt
membran
depolar
mode
viii
electropor
model
model
nonmutu
exclus
allow
singl
amp
might
present
multiplehit
strategi
base
two
simultan
mechan
toroid
model
amp
bind
membran
form
flipflop
transloc
channel
open
membran
vertic
amp
remain
close
associ
lipid
headgroup
throughout
process
carpet
model
provid
disrupt
membran
without
intern
amp
contrast
amp
remain
associ
membran
crucial
concentr
peptid
contribut
weaken
hydrophob
interact
structur
phospholipid
amp
form
carpet
structur
increas
membran
disrupt
aggreg
model
amp
detergentlik
role
interweav
phospholipid
disaggreg
similar
true
deterg
depend
amp
membran
composit
mode
action
provid
membran
ruptur
instead
form
thin
channel
cross
amp
molecul
cell
barrel
model
provid
format
regularli
organ
aggreg
amp
interact
associ
membran
amp
oligom
lead
format
pore
lipid
bilay
intim
interact
hydrophob
side
chain
hydrophob
part
membran
transmembran
pore
allow
intern
hydrophil
part
amp
face
intern
region
membran
lastli
model
share
similar
four
classic
model
disord
toroid
model
mode
action
provid
stochast
pore
format
inward
lipid
distort
allow
aggreg
maximum
two
peptid
center
pore
howev
extern
peripher
region
pore
mani
peptid
set
transloc
undisrupt
mechan
base
amp
cross
membran
combin
featur
amp
sequenc
membran
composit
inhibit
reaction
cellular
metabol
caus
cell
death
two
differ
way
amp
enter
cell
first
obscur
spontan
transloc
across
membran
mainli
result
presenc
secondari
structur
amp
caus
membran
permeabil
method
name
shaimatsuzakihuang
method
ahel
amp
bind
parallel
membran
hydrophob
residu
face
membran
permit
intern
part
amp
chang
organ
transvers
mode
form
toroid
pore
model
suggest
bsheet
amp
organ
flataggreg
form
allow
insert
aromat
residu
membran
open
thin
transloc
space
amp
cross
membran
across
membran
amp
target
varieti
intracellular
site
gene
promot
code
sequenc
mrnabind
site
enzym
regulatori
site
protein
prefold
site
inhibitori
interact
involv
block
dna
transcript
andor
rna
translat
incorrect
protein
fold
trigger
failur
metabol
pathway
cell
death
recent
new
undisrupt
mechan
discov
ampsensit
bacteria
speci
escherichia
coli
salmonella
spp
evolv
abil
detect
prevent
amp
antibacteri
activ
trigger
pathway
involv
sens
amplifi
resist
cation
amp
resist
provid
phoqphop
system
e
coli
compris
activ
amp
detector
kinas
phoq
mg
ca
phosphoryl
activ
transcript
factor
phop
activ
phop
activ
pagp
encod
resist
enzym
amp
mgta
encod
transport
mg
hdea
encod
chaperon
respons
acid
condit
phosphoryl
phop
activ
transcript
quee
gene
encod
enzym
control
biosynthesi
hypermodifi
guanosin
found
rare
trna
overexpress
inhibit
cell
divis
downregul
bacteri
divisom
subleth
concentr
amp
highli
cation
amphiphil
peptid
deriv
ctermin
sequenc
human
protein
platelet
factor
trigger
phoqdepend
filament
wildtyp
e
coli
overexpress
quee
bacteri
filament
ten
hundr
micron
length
prevent
fulli
bacteri
growth
detect
genet
engin
strain
phopregul
promot
drive
transcript
yellow
fluoresc
protein
anoth
good
exampl
buforin
ii
potent
amp
chines
toad
bufo
gargarizan
antimicrobi
activ
rang
microorgan
insid
cell
buforin
ii
inhibit
gene
express
associ
dna
mrna
transcript
translat
occur
melittin
bee
venom
peptid
activ
gramposit
gramneg
bacteria
well
pathogen
fungi
typic
exampl
nondisrupt
amp
discov
late
support
carpet
model
microorgan
inhibit
detail
develop
antibiot
major
impact
modern
medicin
howev
increas
emerg
antibiot
resist
limit
develop
novel
class
antibiot
past
four
decad
led
scenario
infect
longer
treatabl
avail
antibiot
antimicrobi
resist
amr
defin
resist
microorgan
antimicrobi
sensit
amr
inevit
evolutionari
outcom
organ
develop
genet
mutat
improv
fit
lead
select
respons
select
pressur
environ
fact
pathogen
bacteria
resist
least
one
type
antibiot
undesir
select
microbi
cell
resistanceconf
mutat
resist
element
repres
main
drawback
longterm
treatment
effici
patient
lead
intens
medic
research
discov
new
target
overcom
multidrug
resist
mdr
current
class
antibiot
face
constant
threat
repres
divers
bacteri
resist
mechan
eskap
pathogen
enterococcu
faecium
staphylococcu
aureu
klebsiella
pneumonia
acinetobact
baumannii
pseudomona
aeruginosa
enterobact
speci
repres
danger
pathogen
immunocompromis
patient
commonli
isol
drugresist
dr
mdr
microorgan
two
major
way
common
bacteria
evolv
becom
resist
intrins
acquir
resist
amp
intrins
resist
occur
natur
consequ
presenc
amp
natur
environ
bacteria
develop
mechan
resist
antibiot
action
happen
via
passiv
induc
mechan
passiv
resist
alway
associ
less
tight
interact
bacteria
amp
inher
accumul
posit
charg
lipid
common
genera
proteu
providencia
burkholderia
morganella
serratia
induc
resist
consequ
perenni
revers
modif
molecular
level
gramposit
gramneg
bacteria
acquir
resist
product
highfit
mutant
often
contain
one
mutat
unrel
amp
select
bacteri
mutat
gene
provid
alter
genet
system
allow
bacteri
growth
presenc
amp
identifi
experiment
procedur
without
amp
cultur
media
bacteri
om
inner
membran
architectur
alter
site
ligat
amp
protect
respons
reduc
level
ca
mg
specif
protein
chang
lipid
composit
consider
reduc
membran
fluiditi
permeabl
polymyxin
defensin
cathelicidin
bacteri
membran
phospholipid
content
phosphatidylethanolamin
pe
phosphatidylglycerol
pg
cardiolipin
cl
reflect
global
state
protect
pore
format
biosynthesi
turnov
transloc
phospholipid
target
site
membran
modul
express
protein
close
relat
resist
amp
profil
cation
amp
resist
shown
increas
total
content
cl
liposom
model
membran
strain
aureu
resist
methicillin
exampl
increas
lipid
biosynthesi
transloc
membran
simpli
activ
gene
encod
multipl
peptid
resist
factor
mprf
cardiolipin
synthas
cl
phosphatidylglycerol
synthas
pgsa
affin
cell
membran
amp
consider
reduc
minim
neg
charg
phospholipid
bilay
ie
lipid
composit
addit
twocompon
signal
regulatori
system
tc
phoq
phop
system
p
aeruginosa
apsrapss
staphylococcu
epidermidi
act
togeth
lipid
modif
enhanc
resist
cation
amp
cell
wall
outer
barrier
act
secondari
physic
protect
structur
pore
format
bacteria
give
strength
bacteri
cell
influenc
final
cell
format
amp
often
establish
ionic
andor
hydrophob
interact
cell
wall
modif
polysaccharid
bilay
peptidoglycan
teichoic
acid
cell
wall
particularli
interest
gramposit
bacteria
ampcel
wall
interact
avoid
aureu
staphylococcu
xylosu
present
multipl
copi
dlt
operon
regulatori
sequenc
activ
promot
dalanyl
teichoic
acid
cell
wall
reduc
anion
charg
gramneg
bacteria
affin
lipopolysaccharid
lp
om
cation
amp
reduc
increas
posit
charg
lipid
substitu
palmit
phosphoethanolamin
phosphat
group
modif
lipid
also
induc
phoqphop
system
appear
close
relat
cation
amp
resist
mainli
polymyxin
b
gramneg
bacteria
glycosyl
lipid
recent
report
anoth
lipid
modif
result
polymyxin
resist
ei
tor
vibrio
cholera
addit
glycin
lipid
regul
almefg
operon
control
express
sever
protein
aim
almf
almg
relat
glycin
activ
transfer
lipid
glycin
activ
adenyl
alm
transfer
activ
glycin
phosphopantethein
group
almf
activ
almf
donat
glycin
hydroxylauryl
chain
lipid
transfer
reaction
perform
almg
bacteria
commonli
state
thicker
cell
wall
less
effici
antibiot
extens
amp
improv
cell
wall
thick
strategi
adopt
aureu
erythromycin
vancomycin
acriflavin
mani
amp
cell
wall
peptidoglycan
layer
increas
thick
upregul
glutamin
synthas
e
coli
strain
resist
magainin
ii
characterist
absent
suscept
strain
bacteria
arsen
molecul
prevent
cellular
metabol
suffer
stress
caus
amp
sever
pathway
upor
downregul
increas
biosynthesi
proteas
modif
membran
site
recogniz
amp
overproduct
biofilm
suppress
superfici
element
relat
pore
format
inher
mechan
amp
resist
bacteria
partial
total
proteolyt
cleavag
amp
strain
aureu
overproduc
metalloproteas
aureolysin
resist
cathelicidin
proteu
mirabili
produc
high
amount
metalloproteas
zapa
avoid
antimicrobi
activ
bdefensin
simpli
break
protein
six
nine
innocu
peptid
system
upregul
biosynthesi
bacteria
proteas
discuss
elsewher
nisin
resist
gene
nr
resist
strain
lactococcu
lacti
central
element
nisincontrol
gene
express
system
nice
proteas
encod
nr
gene
cleav
c
terminu
nisin
confer
vitro
resist
nonnisinproduc
l
lacti
analog
speb
cystein
proteas
streptococcu
pyogen
catalyz
proteolysi
vitro
patient
infect
resist
bacteria
stress
caus
amp
pyogen
synthes
grelat
grab
protein
act
potent
inhibitor
proteas
inhibitor
form
cluster
name
complex
retain
activ
speb
bacteri
surfac
posterior
cleavag
caus
bacteri
resist
molecular
trap
captur
amp
biofilm
product
also
import
resist
mechan
evolv
differ
speci
bacteria
exampl
l
lacti
express
pilb
pilu
backbon
protein
gramposit
bacteria
trap
cathelicidin
along
cell
wall
avoid
contact
cytoplasm
membran
biofilmproduc
bacteria
resist
mani
differ
antibiot
biofilmmedi
resist
result
mainli
extracellular
polymer
substanc
ep
liquid
compris
mainli
amyloid
adhes
fimbria
extracellular
dna
exopolysaccharid
emb
multipl
cell
throughout
biofilm
matrix
ep
extracellular
dna
p
aeruginosa
induc
resist
polymyxin
b
colistin
respons
chelat
environment
cation
decreas
concentr
biofilm
cation
modul
upregul
lp
modif
gene
associ
resist
typic
mechan
resist
strain
p
aeruginosa
addit
natur
antimicrobi
activ
amp
also
potenti
applic
therapi
treatment
diseas
exampl
amp
antitumor
immunomodulatori
activ
peptid
import
drug
candid
known
anticanc
peptid
acp
host
defens
peptid
hdp
respect
sever
acp
show
improv
absorpt
higher
specif
cytotox
tumor
cell
fewer
advers
effect
compar
chemic
agent
high
number
interact
acp
tumor
receptor
could
result
presenc
abund
anion
site
dispers
tumor
cell
result
rapid
select
bind
cell
death
contrast
hdp
frequent
show
weak
antimicrobi
activ
mammal
potent
trigger
immun
respons
varieti
mechan
affect
innat
immun
host
peptid
divers
structur
sequenc
constant
interact
differ
microbi
cell
present
multipl
infect
strategi
innat
immun
system
mammal
show
characterist
nonspecif
quick
antimicrobi
therapi
mediat
activ
element
resist
pathogen
hdp
act
trigger
immun
respons
element
sever
mechan
upregul
express
hundr
gene
monocyt
epitheli
cell
induct
differenti
respons
chemokin
synthesi
promot
angiogenesi
inflammatori
woundheal
respons
therapeut
peptid
alreadi
reach
market
statu
peptid
current
avail
market
usa
estim
approxim
therapeut
peptid
reach
preclin
trial
includ
clinic
trial
usa
despit
develop
mani
potenti
pharmaceut
peptid
road
market
restrict
drug
candid
must
meet
sever
requir
similar
higher
efficaci
toler
compar
alreadi
exist
analog
drug
improv
pharmacodynam
pharmacokinet
low
toxic
safe
use
econom
issu
must
also
satisfi
mainli
relat
market
competit
scalabl
product
intellectu
properti
reason
novel
therapeut
candid
fail
achiev
market
statu
regul
surround
use
molecul
also
determin
base
physicochem
properti
manufactur
peptid
us
food
drug
administr
fda
usual
rank
peptid
convent
drug
mostli
chemic
structur
exceed
residu
although
except
made
mostli
case
vaccin
rank
biolog
product
europ
european
medicin
agenc
ema
evalu
sourc
peptid
molecul
screen
natur
biolog
sourc
treat
biolog
entiti
contrast
chemic
entiti
chemic
synthes
vitro
addit
manufactur
must
guarante
ident
puriti
potenc
individu
lot
consist
exampl
drug
candid
failur
perhap
common
might
expect
famou
case
peptid
magainin
pexiganan
potent
amp
isol
african
claw
frog
xenopu
laevi
complet
phase
clinic
trial
fda
approv
commerci
drug
prove
effect
compar
antibiot
util
trial
notabl
expans
peptidebas
drug
discoveri
field
past
year
encourag
screen
test
new
drug
candid
approv
rate
sinc
peptid
around
reflect
increas
number
peptid
enter
annual
clinic
trial
one
compar
candid
enter
phase
clinic
trial
painkil
anticanc
anticardiovascular
diseas
agent
acp
domin
phase
clinic
trial
follow
painkil
antiinfecti
diseas
antiallergen
agent
histor
search
new
effici
amp
base
highthroughput
screen
ht
biolog
activ
molecul
concept
reli
discoveri
natur
occur
peptid
use
classic
purif
vitro
vivo
techniqu
check
antimicrobi
activ
mani
amp
identifi
test
clinic
natur
strain
pathogen
use
approach
bioactiv
peptid
obtain
natur
sourc
evolutionari
pressur
millennia
consist
show
high
stabil
target
affin
andor
specif
howev
natur
occur
amp
normal
synthes
low
rate
biolog
sourc
mani
suscept
proteas
degrad
low
bioavail
ie
presenc
bioactiv
molecul
usual
low
level
despit
recent
advanc
ht
techniqu
approach
labori
difficult
produc
high
yield
peptid
scalabl
fashion
new
amp
potent
antimicrobi
activ
lower
propens
select
drug
resist
intens
investig
silico
methodolog
ration
design
peptid
aim
improv
biolog
activ
increas
product
effici
speed
biosynthesi
decreas
product
cost
ration
tailor
peptid
repres
new
gener
design
drug
simultan
overcom
pathogen
resist
enhanc
microbi
kill
amp
design
base
primarili
structurefunct
relat
hostderiv
synthet
amp
comput
analysi
surfac
interact
peptid
pathogen
structur
three
main
way
enhanc
peptid
activ
comput
design
epitop
net
charg
engin
de
novo
sequenc
optim
amp
motif
ii
chang
posttransl
pattern
glycosyl
peptid
amino
acid
substitut
glycosyl
site
iii
engin
differ
peptid
chimer
molecul
andor
biomateri
surfac
amp
properti
sequenc
optim
motif
mainli
appli
design
cation
ahel
amp
improv
specif
antimicrobi
activ
low
toxic
mammalian
cell
divers
engin
cation
antimicrobi
peptid
ecap
synthet
produc
laboratori
worldwid
show
rang
vitro
vivo
antimicrobi
activ
examin
structurefunct
relat
primarili
perform
predict
protein
interfac
infer
proteinprotein
proteinlipid
interact
network
interfac
predict
base
physicochem
properti
residu
interfac
protein
complex
overlap
interfac
noninterfac
segment
protein
motif
promin
characterist
amp
peptid
design
sequenc
conserv
interfac
residu
proport
type
amino
acid
residu
rel
presenc
secondari
structur
solvent
access
sidechain
conform
entropi
amp
synthes
glycoconjug
peptid
carri
varieti
olink
glycan
crucial
peptid
recognit
bind
proteinprotein
interact
surfac
glycan
posttransl
ad
golgi
peptid
pass
secretori
pathway
plantderiv
amp
main
primari
target
glycosyl
engin
aim
improv
biolog
activ
phytopathogen
human
glycosyl
clinic
use
human
plant
nglycan
differ
consider
mammal
typic
mammalian
fucos
nacetylglucosamin
core
bmannos
core
galactos
combin
sialic
acid
link
termin
nacetylglucosamin
substitut
plant
fucos
bisect
xylos
galactos
fucos
termin
nacetylglucosamin
respect
anoth
import
issu
concern
human
amp
glycosyl
avoid
addit
allergen
glycoepitop
peptid
surfac
human
frequent
allerg
plant
fucos
xylos
current
main
effort
minim
undesir
plant
glycosyl
amp
reli
avoid
complet
transit
throughout
secretori
pathway
confin
peptid
insid
endoplasm
reticulum
use
ctermin
retent
signal
kdel
advanc
human
glycosyl
protein
ie
full
substitut
nonmammalian
host
nlink
glycan
typic
human
glycan
knock
plant
xylosyl
fucosyltransferas
yeast
mannosidas
express
human
glycosidas
alreadi
realiti
product
plant
yeast
antibodi
interferon
yet
fulli
appli
amp
chimer
ecap
anoth
major
group
engin
amp
synthes
chemic
recombinantli
fusion
peptid
antimicrobi
surfaceco
agent
base
potenti
synergist
effect
multipl
activ
epitop
consider
enhanc
antimicrobi
activ
featur
reveal
interest
aspect
chimer
ecap
name
potenti
prevent
bacteri
colon
biofilm
format
promis
approach
elimin
implant
infect
synthesi
individu
domain
chimer
ecap
must
present
solidbind
kinet
nanoformul
surfac
substrat
without
loss
antimicrobi
properti
peptid
remain
one
promis
engin
antiinfect
agent
popular
opportunist
pathogen
postop
care
set
natur
occur
amp
typic
subject
proteolysi
compris
lamino
acid
recogniz
proteas
minim
peptid
degrad
ration
design
sequenc
compris
analog
damino
acid
substitut
lamino
acid
consist
increas
peptid
posttransl
stabil
without
alter
biolog
function
given
interact
amp
bacteri
membran
strictli
depend
interact
mediat
specif
receptor
denantiom
peptid
often
retain
antimicrobi
activ
anoth
interest
modif
ecap
addit
polyalanin
tail
n
c
terminu
peptid
amino
acid
alanin
moder
hydrophob
polymer
repetit
peptid
tail
exceed
hydrophob
limit
insert
mechan
cytoplasm
membran
polyalanin
peptid
insert
membran
microb
without
caus
signific
phospholipid
displac
maintain
bilay
integr
also
intern
within
cell
modif
metabol
pathway
therefor
polyalanin
tail
induc
undesir
peptid
configur
lead
format
peptid
cluster
unabl
anchor
lipid
bilay
one
promis
modif
ecap
structur
peglyat
coval
addit
polyethylen
glycol
peg
chain
peptid
peglyat
provid
improv
structur
stabil
higher
bioavail
modifi
peptid
protein
pegyl
synthet
ecap
retain
antimicrobi
activ
higher
target
specif
although
superflu
coval
attach
peg
moieti
reduc
interact
ecap
target
site
cytoplasm
membran
bacteria
peptid
show
therapeut
function
must
inject
bloodstream
either
pure
form
nanoencapsul
case
stabil
peptid
must
preserv
maintain
high
level
bioactiv
peptid
cycliz
major
strategi
improv
serum
stabil
synthet
peptid
join
n
c
terminu
backbon
format
intern
cross
disulfid
bridg
cycliz
peptid
hide
proteolyt
cleavag
site
specif
cellular
aminopeptidas
amid
c
terminu
peptid
appear
gener
improv
antimicrobi
activ
stabil
gener
amid
peptid
exhibit
higher
antimicrobi
activ
amid
c
terminu
affect
hydrophob
moment
synthet
peptid
corrobor
enhanc
interact
membran
although
import
strategi
improv
microbi
death
also
appear
improv
hemolyt
activ
requir
casebycas
studi
evalu
pro
con
modif
follow
accur
predict
structur
chang
engin
peptid
chemic
synthes
routin
produc
mani
genet
engin
strategi
fig
context
silico
interact
databas
valuabl
tool
predict
site
peptid
physic
interact
microbi
cell
optim
motif
architectur
net
charg
amino
acid
replac
mani
exampl
ration
design
amp
alreadi
describ
literatur
show
true
potenti
futur
use
clinic
set
often
ecap
present
enhanc
biolog
activ
mdr
microorgan
also
lower
propens
select
resist
bacteria
vitro
compar
nativ
analog
tabl
list
promis
ecap
therapeut
use
mdr
microb
prospect
improv
silico
select
amp
must
produc
larg
scale
consist
high
qualiti
good
manufactur
practic
rule
gmp
size
chemic
properti
given
peptid
directli
influenc
choic
product
strategi
least
four
major
strategi
achiev
satisfactori
yield
highqual
product
solidst
chemic
synthesi
ii
recombin
microb
platform
iii
transgen
plant
anim
iv
cellfre
express
system
regardless
method
use
downstream
process
crucial
step
commerci
peptid
expens
timeconsum
test
phase
product
pipelin
special
design
strain
bacteria
fungal
accumul
induc
mutat
typic
util
reactor
natur
occur
amp
strain
enhanc
protein
synthesi
secret
well
upgrad
peptid
fold
circumst
peptid
yield
increas
three
order
magnitud
mani
case
product
level
still
standard
product
level
requir
altern
natur
sourc
product
technolog
result
chemic
synthesi
partial
full
peptid
chain
three
type
chemic
synthesi
solut
phase
ii
solid
phase
iii
hybrid
approach
commerci
approv
peptid
frequent
small
medium
size
synthes
solut
phase
approach
methodolog
provid
standard
protocol
isol
character
purif
peptid
solidphas
synthesi
provid
platform
product
larg
structur
complex
peptid
larg
scale
hybrid
method
combin
characterist
two
previou
methodolog
although
effici
product
activ
peptid
three
approach
expens
enabl
prolong
maxim
peptid
biosynthesi
genet
engin
bacteria
yeast
cell
frequent
explor
vehicl
recombin
product
bioactiv
amp
mani
differ
amp
synthes
e
coli
pichia
pastori
despit
high
therapeut
potenti
recombin
amp
limit
invest
compani
drawback
term
poor
yield
low
qualiti
unsatisfactori
vivo
activ
restrict
commerci
develop
promis
amp
regardless
product
limit
therapeut
peptid
reach
advanc
clinic
trial
commerci
detail
tabl
among
import
factor
limit
recombin
product
amp
microbi
system
inner
toxic
peptid
toward
host
cell
howev
typic
limit
mani
amp
kill
bacteria
low
nontox
concentr
anoth
concern
low
qualiti
peptid
product
follow
posttransl
modif
circumst
plant
appear
interest
promis
altern
host
system
product
recombin
amp
although
plant
perform
rang
posttransl
modif
low
level
recombin
biosynthesi
peptid
common
result
low
quantiti
purifi
product
howev
new
transform
technolog
call
magnifect
emerg
platform
fast
product
larg
number
plantderiv
recombin
protein
peptid
develop
gleba
collabor
german
biotech
compani
icon
genet
magnifect
transient
express
platform
util
nicotinia
tabacum
nicotinia
benthamiana
plant
effici
reactor
product
massiv
yield
recombin
protein
rapid
scalabl
fashion
process
base
infiltr
whole
plant
suspens
transgen
agrobacterium
tumefacien
cell
carri
plasmid
encod
viral
rna
replicon
fig
gramneg
soil
bacteria
key
role
infect
movement
throughout
plant
tissu
system
spread
plant
eventu
reach
leav
stem
infiltr
plant
contain
viral
vector
base
tobacco
mosaic
viru
tmv
potato
viru
x
pvx
carri
ampcod
sequenc
deliv
bacteria
transient
express
amplifi
potent
machin
transcript
product
use
viral
machineri
enhanc
product
viral
protein
along
select
amp
without
stabl
transgen
integr
result
massiv
yield
amp
speed
one
main
advantag
magnifect
provid
express
kinet
frequent
reach
peak
peptid
product
day
infiltr
condit
allow
scaleup
plant
infiltr
vacuum
peptid
biosynthesi
combin
element
three
biolog
system
ie
viral
potent
transcript
bacteri
system
spread
plant
accur
posttransl
modif
singl
express
strategi
therefor
magnifect
significantli
reduc
amp
product
cost
rapid
straightforward
approach
result
product
first
milligram
amp
week
kg
year
use
muchdilut
tumefacien
suspens
infiltr
complet
entir
green
hous
high
biomass
tobacco
kg
ha
also
contribut
scale
peptid
product
reduc
overal
cost
use
magnifect
protein
peptid
amount
frequent
higher
observ
stabl
genet
transform
plant
yield
total
solubl
protein
tsp
use
technolog
amount
g
peptid
per
kilogram
fresh
agroinfiltr
leav
obtain
routin
magnifect
platform
experienc
consider
success
product
varieti
protein
peptid
notabl
vaccin
small
size
antigen
peptid
rel
simpl
chemic
structur
amp
appear
fulfil
requir
platform
sinc
magnifect
system
explor
canadian
biotech
compani
medicago
http
wwwmedicagocom
industri
product
vaccin
flu
usa
us
million
budget
financi
deal
sign
medicago
us
depart
defens
agenc
defens
advanc
research
project
agenc
darpa
develop
million
dose
per
month
avoid
risk
epidem
flu
outbreak
vaccin
current
phase
clinic
trial
anoth
vaccin
variant
viru
synthes
use
platform
tabl
detail
vaccin
alreadi
synthes
tobacco
use
magnifect
system
although
effici
transient
biosynthesi
peptid
addit
plantspecif
posttransl
modif
notabl
addit
nglycan
peptid
potenti
limit
system
could
lead
nonfunct
product
highli
immunogen
vaccin
threshold
econom
accept
express
level
use
magnifect
restrict
factor
similar
previous
explor
recombin
platform
although
good
produc
full
antibodi
size
multimer
protein
constitut
anoth
import
challeng
magnifect
system
requir
manipul
two
viral
vector
express
two
assembl
polypeptid
genom
edit
crispr
amp
biosynthesi
advanc
implic
challeng
screen
assembl
technic
challeng
typic
bind
short
sequenc
replac
fragment
longer
kb
difficult
offtarget
effect
target
event
anim
requir
screen
larger
zfn
code
usual
dna
evid
larger
talen
lead
less
specif
offtarget
effect
crispr
recent
discov
bacteri
adapt
immun
system
use
combin
short
rna
associ
protein
target
specif
sequenc
dna
gener
dsb
crispr
revolution
genom
edit
standard
present
sever
technic
advantag
compar
previou
system
although
still
disadvantag
easili
adapt
system
target
modifi
genom
sequenc
protein
main
protein
dna
recognit
cleavag
remain
unchang
crispr
easi
use
target
numer
site
across
genom
librari
use
multiplexbas
guid
rna
simultan
edit
multipl
site
size
cdna
approxim
kb
express
level
improv
product
qualiti
howev
frequent
gene
silenc
transcript
level
instabl
gene
clone
vector
stabl
transient
express
remain
major
challeng
limit
effici
product
amp
anoth
persist
issu
poor
qualiti
peptid
endogen
synthes
bacteria
yeast
plant
particularli
result
undesir
posttransl
modif
improv
target
genom
engin
repres
sophist
approach
could
help
minim
limit
past
decad
altern
genomeedit
tool
artifici
engin
enzym
zincfing
nucleas
zfn
transcriptionactivatorlik
effector
nucleas
talen
success
util
modifi
genom
microb
plant
anim
ad
remov
replac
segment
dna
effici
less
timeconsum
technolog
genom
engin
develop
recent
appear
consider
expand
possibl
modif
target
site
almost
sequenc
genom
cluster
regularli
interspac
short
palindrom
repeat
system
crispr
box
convent
genomeedit
system
use
synthet
nucleas
induc
genom
doublestrand
break
dsb
target
site
dsb
target
imprecis
cellular
repair
machineri
either
mediat
nonhomolog
endjoin
nhej
homolog
direct
repair
hdr
requir
donor
dna
templat
crispr
constitut
incred
versatil
genomeedit
platform
deriv
pyogen
crisprassoci
protein
three
type
crispr
type
ii
simplest
present
bacteria
compris
four
protein
ie
wide
use
system
gene
engin
popular
crisprca
system
constitut
endonucleas
protein
crispr
rna
nucleas
catalyz
precis
cleavag
target
site
assist
two
short
helper
rna
crna
tracrna
fusion
rna
form
hybrid
singl
guid
rna
sgrna
bind
form
supramolecular
complex
name
rnaguid
endonucleas
sequencespecif
recogn
complex
cleav
specif
site
genom
result
dsb
repair
preferenti
hdr
case
bacteri
genom
thu
alter
genom
precis
manner
sitespecif
modif
system
use
introduc
point
mutat
modifi
gene
function
gener
gene
knockout
integr
foreign
gene
repress
andor
activ
specif
gene
deliv
epigenet
modif
aid
genom
loci
access
protein
although
limit
studi
report
util
type
ii
crisprsca
system
edit
plant
genom
exploit
edit
organ
crisprca
system
ii
technolog
descript
amp
biosynthesi
mediat
genom
edit
spacer
acquisit
format
crispr
array
recognit
integr
foreign
dna
spacer
within
crispr
locu
fulli
synthes
genet
engin
protospac
noncod
region
insert
bacteri
dna
bp
adjac
protospac
found
bp
short
dna
sequenc
term
protospac
adjac
motif
pam
crrna
process
b
crispr
array
transcrib
long
rna
precrrna
cleav
crrna
help
ca
protein
extra
small
rna
tracrrna
complementari
repeat
sequenc
also
synthes
c
tracrrna
pair
repeat
region
crrna
help
process
precrrna
crrna
help
rnase
iii
cleavag
interfer
stage
crrna
bind
ca
protein
form
complex
recogn
foreign
dna
e
singl
multifunct
protein
recruit
crrna
tracrrna
cleav
recogn
foreign
dna
use
intern
endonucleas
domain
f
process
base
recognit
pair
pam
foreign
dna
doubl
strand
break
dsb
gener
g
donor
dna
contain
code
sequenc
amp
interest
integr
site
dsb
homolog
recombin
gene
express
amp
extract
purifi
h
addit
genom
edit
crisprca
system
util
purpos
within
cell
instanc
gene
silenc
crispr
interfer
crispri
prove
power
tool
complement
mani
case
improv
previous
describ
rnai
doubl
format
bound
sgrna
attach
nontempl
strand
dna
block
transcript
approach
also
util
simultan
silenc
multipl
target
gene
process
call
multiplex
thu
overcom
one
limit
rnai
term
gene
silenc
potenti
anoth
interest
applic
crisprca
block
transcript
initi
specif
revers
manner
immens
potenti
util
crispr
improv
recombin
biosynthesi
amp
almost
organ
tailor
genom
modifi
crispr
harbor
amp
code
sequenc
within
donor
dna
fragment
insert
genom
express
hot
spot
potenti
boost
heterolog
product
peptid
unpreced
level
fig
reduc
undesir
posttransl
modif
amp
might
possibl
knockout
host
glycosylas
gene
substitut
code
sequenc
human
glycosylas
human
glycopeptid
could
contribut
enhanc
antimicrobi
activ
therapeut
peptid
qualiti
puriti
lack
undesir
posttransl
modif
high
level
among
other
addit
glycosyl
posttransl
modif
peptideprocess
pathway
could
manipul
crisprca
crisprca
repres
promis
technolog
improv
peptid
engin
biosynthesi
push
boundari
develop
clinic
drug
new
level
sophist
major
concern
util
crispr
genomeedit
tool
potenti
secondari
mutat
offtarget
effect
common
scenario
human
edit
cell
howev
ontarget
effici
recent
improv
still
rare
plant
avoid
offtarget
effect
imper
properli
design
sgrna
direct
exact
target
genom
effort
along
line
publish
recent
addit
high
level
nucleas
rel
sgrna
help
reduc
incid
offtarget
effect
nucleas
engin
nickas
cleav
singl
strand
dna
strategi
strand
enhanc
specif
site
recognit
consist
minim
offtarget
effect
prospect
novel
effici
amp
crucial
start
point
combat
antibioticresist
microbi
pathogen
emerg
mdr
bacteria
tremend
global
health
problem
predict
lead
death
million
human
per
year
microb
plant
anim
natur
sourc
therapeut
drug
could
also
sourc
novel
biolog
inspir
previous
unknown
antibiot
human
applic
addit
obviou
import
novel
amp
high
antiinfect
properti
difficult
prospect
natur
synthes
low
level
respect
host
organ
therefor
urgent
need
increas
effici
final
yield
peptid
product
allow
econom
exploit
new
insight
ration
design
peptid
requir
maxim
amp
variabl
increas
specif
antimicrobi
activ
current
exampl
synthet
recombin
amp
tailor
domain
face
advanc
clinic
trial
promis
result
ration
design
molecul
present
modifi
epitop
improv
net
charg
enhanc
antimicrobi
activ
repres
new
gener
antiinfect
agent
potenti
overcom
mdr
transient
express
amp
gene
tobacco
new
technolog
immens
potenti
consider
boost
heterolog
product
new
antibiot
vaccin
fast
cheap
effici
way
use
potent
viral
vector
associ
bacteri
deliveri
transcript
unit
provid
scalabl
platform
massiv
product
diversifi
amp
potenti
desir
improv
term
process
product
cost
drawback
present
plant
express
system
solv
crispr
system
revolutionari
genomeedit
technolog
present
myriad
possibl
genet
manipul
genom
level
provid
unpreced
tool
crispri
crispra
precis
control
gene
express
structur
modif
amp
despit
current
minor
limit
eg
offtarget
effect
crispr
could
key
role
futur
develop
clinic
drug
biotechnolog
antiinfect
agent
includ
ration
biosynthesi
nextgener
antimicrobi
